Bruker has announced the planned discontinuation of the IsoSpark and IsoLight platforms. Customers with questions about transition options and last-time-buy opportunities should contact their Bruker sales representative.

Row rect Shape Decorative svg added to bottom
Back to Webinars
Rational Design of a Trimeric April-Based CAR-Binding Domain Enables Efficient Targeting of Multiple Myeloma

Featured Speakers: Andrea Schmidts, Post Doctoral Research Fellow, MD Cellular Immunotherapy Program, MGH Cancer Center and Harvard Medical School

What's Inside

In this Webinar we discuss:

Discover how a trimeric extracellular moiety of APRIL has enhanced binding to BCMA and TACI compared with monomeric APRIL when incorporated into a CAR

Explore why trimeric APRIL-based CAR are efficient against BCMA-negative multiple myeloma

Learn why T cells transduced with a trimeric APRIL-based CAR are a promising approach for the treatment of multiple myeloma

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Row rect Shape Decorative svg added to top
Watch the Webinar
Back to the Top